Phillip Md Et Al Frost Purchases 150,000 Shares of OPKO Health, Inc. (NASDAQ:OPK) Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost acquired 150,000 shares of the stock in a transaction that occurred on Friday, March 28th. The shares were acquired at an average cost of $1.70 per share, with a total value of $255,000.00. Following the transaction, the chief executive officer now owns 213,651,448 shares in the company, valued at approximately $363,207,461.60. The trade was a 0.07 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Monday, March 17th, Phillip Md Et Al Frost bought 200,000 shares of OPKO Health stock. The stock was bought at an average price of $1.74 per share, with a total value of $348,000.00.
• On Friday, February 28th, Phillip Md Et Al Frost purchased 67,434 shares of OPKO Health stock. The stock was bought at an average cost of $1.71 per share, for a total transaction of $115,312.14.
• On Tuesday, January 28th, Phillip Md Et Al Frost acquired 47,537 shares of OPKO Health stock. The shares were bought at an average price of $1.47 per share, with a total value of $69,879.39.
• On Friday, January 17th, Phillip Md Et Al Frost bought 150,000 shares of OPKO Health stock. The stock was bought at an average price of $1.47 per share, for a total transaction of $220,500.00.
• On Wednesday, January 15th, Phillip Md Et Al Frost purchased 500,000 shares of OPKO Health stock. The shares were purchased at an average price of $1.48 per share, with a total value of $740,000.00.

OPKO Health Stock Performance

Shares of OPK opened at $1.70 on Friday. OPKO Health, Inc. has a 52-week low of $1.15 and a 52-week high of $2.04. The firm has a market capitalization of $1.14 billion, a PE ratio of -8.95 and a beta of 1.70. The firm has a 50-day moving average price of $1.68 and a 200 day moving average price of $1.58. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.09. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The business had revenue of $183.60 million during the quarter, compared to analysts’ expectations of $155.42 million. On average, sell-side analysts anticipate that OPKO Health, Inc. will post -0.25 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. StockNews.com raised shares of OPKO Health from a “sell” rating to a “hold” rating in a research note on Monday, March 3rd. HC Wainwright reiterated a “buy” rating and set a $3.00 price objective on shares of OPKO Health in a research report on Wednesday, March 19th. Finally, Barrington Research restated an “outperform” rating and issued a $2.25 target price on shares of OPKO Health in a research report on Wednesday, March 12th.

Institutional Trading of OPKO Health

A number of hedge funds and other institutional investors have recently modified their holdings of OPK. Barclays PLC grew its holdings in OPKO Health by 154.5% during the third quarter. Barclays PLC now owns 543,336 shares of the biotechnology company’s stock worth $810,000 after acquiring an additional 329,870 shares during the period. BNP Paribas Financial Markets boosted its position in shares of OPKO Health by 736.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 246,967 shares of the biotechnology company’s stock valued at $368,000 after purchasing an additional 217,450 shares in the last quarter. Intech Investment Management LLC acquired a new position in shares of OPKO Health in the 3rd quarter worth approximately $190,000. FMR LLC raised its holdings in shares of OPKO Health by 103.6% in the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 11,089 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new stake in OPKO Health during the fourth quarter valued at approximately $102,000. Institutional investors own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.